Last edition
News about "Breakthrough Therapy"
US FDA Grants Breakthrough Therapy Designation to Lilly's Olomorasib for Advanced Pancreatic Cancer
The US FDA has granted Breakthrough Therapy designation to Eli Lilly's investigational KRAS G12C inhibitor, olomorasib, for treating previously treated advanced pancreatic cancer, reinforcing its potential across difficult-to-treat KRAS-driven cancers.
Breakthrough Therapy | 04/08/2026 | By News Bureau
US Food and Drug Administration Clears Expanded Access Pathway for Daraxonrasib
Regulator issues “safe to proceed” letter to Revolution Medicines, enabling early patient access to investigational therapy for advanced pancreatic cancer.
Breakthrough Therapy | 04/05/2026 | By News Bureau | 396
First-in-class therapy approved to treat agitation linked to Alzheimer’s disease, addressing a major unmet need for patients and caregivers.
Breakthrough Therapy | 04/05/2026 | By News Bureau | 106
FDA Grants Breakthrough Therapy Designation to Biogen's Litifilimab for Cutaneous Lupus
Biogen’s investigational monoclonal antibody litifilimab receives FDA Breakthrough Therapy designation, marking a major step toward targeted treatment for cutaneous lupus erythematosus.
Breakthrough Therapy | 29/01/2026 | By News Bureau | 203
Novartis' Ianalumab Receives FDA Breakthrough Therapy Designation for Sjogren's Disease
The FDA has granted Breakthrough Therapy designation to Novartis’ ianalumab for Sjögren’s disease, accelerating its review as a potential first targeted treatment, with global filings planned from 2026.
Breakthrough Therapy | 19/01/2026 | By News Bureau | 286
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy